ROSETTA GENOMICS
leading the microRNA revolution

miRview™ | meso
Take a closer look

Cat#0803

PATIENT REPORT

Patient Information

Name:
SSN/ID #:
Date of Birth:
Gender:

Account Information

Account name:
Address:
City: State: Zip:
Country:
Phone #:
Fax #:
Report Delivery Preference: ☐ Overnight mail ☐ Fax

Ordering Physician Information

Ordering Physician Name:
Address:
City: State: Zip:
Country:
Phone #:
Fax #:
NPI #:
Report Delivery Preference: ☐ Overnight mail ☐ Fax

Specimen Information

Specimen Type: Formalin-fixed paraffin embedded tissue
Biopsy Site:
Specimen Collection Date:
Subm. Lab Access. #:
Date Specimen Received:
Barcode #:
Sample ID #:
Date Result Reported:

Test Results

Test score 1:
Test score 2:

MESOTHELIOMA

Interpretation of Results

Only when both score 1 and score 2 are positive, mesothelioma is the reported result. Based on validation of the assay, the sensitivity and specificity for discrimination of mesothelioma versus non-mesothelioma tumors in the lung and pleura were 100% and 94% respectively. **Score values obtained near the zero cut-offs (±1.5 from the decision cut-offs) may be more prone to interpretation error.**

Test Description

The miRview ™ meso assay quantifies the expression of three microRNAs and one small RNA to discriminate pleural mesothelioma from other malignancies, primary and metastatic, in the lung and pleura. Initially, an adequate ratio of tumor to surrounding tissue is ascertained, depending on sample characteristics microdissection is performed, and after RNA extraction, qRT-PCR is performed. The cycle threshold (C_T) of hsa-miR-200c, hsa-miR-192, hsa-miR-193a-3p is normalized by the C_T of U6 snRNA and converted via a proprietary algorithm into two numerical scores.

Note

The performance characteristics of this test were determined by Rosetta Genomics in accordance with the requirements of CLIA (Clinical Laboratory Improvement Amendments of 1988).
It has not been cleared or approved by the U.S. Food and Drug Administration. This test is intended to be used for clinical purposes and should not be considered to be for investigational or research use only. Decisions regarding care and treatment should be based on the independent medical judgment of the treating physician taking into consideration all available information concerning the patient's condition, including other tests.

Laboratory Director
Tina Edmonston, MD